We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Orange Juice and Cardiovascular Disease Study (OJ & CVD)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02195934
First Posted: July 21, 2014
Last Update Posted: September 5, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
European Commission
Biotechnology and Biological Sciences Research Council
Information provided by (Responsible Party):
Quadram Institute
  Purpose

This study aims to compare the effect of an anthocyanin-rich blood orange juice with a standard (no anthocyanin) blonde orange juice on markers of cardiovascular disease (CVD).

Participants aged between 25 and 84 years of age will be recruited into a single arm, two way cross-over study based on their waist measurement, with 42 individuals required to complete the study. Participants will each receive two interventions in a randomised order: 500mL blood orange juice daily for 28 days, and 500ml standard (blonde) orange juice daily for 28 days.

Prior to each intervention there will be a 2 week "run in period" where participants will be asked to avoid consuming foods rich in anthocyanins. After the first 28 day intervention period, there will be a 3 week wash out period after which the participants will be asked to then drink the other juice for 28 days. The 500 mL of blood orange juice contains approximately 50mg of anthocyanins, whereas the standard juice contains none.

Blood samples will be collected for the preparation of plasma and peripheral blood mononuclear cells (PBMCs) for the analysis of anthocyanin metabolite concentrations, transcriptomics and CVD risk markers. Urine samples will be collected and urinary excretion of anthocyanin metabolites will be quantified. Other measurements will include pulse wave analysis, pulse wave velocity, central blood pressure, waist and hip circumference, blood glucose, glycated haemoglobin (HbA1C) and insulin concentrations, and various measurements using the TANITA machine which include weight, fat mass, muscle mass, fat percentage, fat-free mass, total body water, bone mass, metabolic age, basal metabolic rate, visceral fat rating, and degree of obesity. All measurements and samples will be taken at baseline and post intervention for each phase of the study.


Condition Intervention
Cardiovascular Disease Other: Standard (blonde) orange juice Other: Blood orange juice

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Orange Juice and Cardiovascular Disease Study

Further study details as provided by Quadram Institute:

Primary Outcome Measures:
  • LDL cholesterol [ Time Frame: 28 days (4 weeks) ]
    The primary outcome measure will be the change in concentration of LDL cholesterol as a result of the daily consumption of standard (blonde) orange juice or blood orange juice for 28 days (4 weeks).


Secondary Outcome Measures:
  • CVD biomarkers [ Time Frame: 28 days (4 weeks) ]
    The secondary outcome measure include measuring the change in concentration of levels of other markers of CVD, HDL, total cholesterol, nitrites, nitrates, nitrosols, interleukin 6, high sensitivity C reactive protein, Dglucose, insulin and endothelin 1 as a result of daily consumption of standard (blonde) orange juice or blood orange juice for 28 days (4 weeks).


Other Outcome Measures:
  • Gene expression [ Time Frame: 28 days (4 weeks) ]
    The assessment of the activity of genes (gene expression) as a result of the daily consumption of standard (blonde) orange juice and blood orange juice for 28 days (4 weeks).


Enrollment: 41
Study Start Date: July 2014
Study Completion Date: August 2016
Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Standard orange juice (OJ) followed by blood OJ
This randomized 2-way cross over study will compare the effect of blood orange juice with that of a standard (blonde) orange juice consumed daily for 28 days, on markers of cardiovascular disease, with a 3 week washout period in between.
Other: Standard (blonde) orange juice
Consumption of 500ml standard (blonde) orange juice daily for 28 days
Other: Blood orange juice
Consumption of 500ml blood orange juice daily for 28 days
Blood orange juice followed by standard OJ
This randomized 2-way cross over study will compare the effect of blood orange juice with that of a standard (blonde) orange juice consumed daily for 28 days, on markers of cardiovascular disease, with a 3 week washout period in between.
Other: Standard (blonde) orange juice
Consumption of 500ml standard (blonde) orange juice daily for 28 days
Other: Blood orange juice
Consumption of 500ml blood orange juice daily for 28 days

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   25 Years to 84 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Men and women aged 25-84 years
  • Waist measurement

    • Caucasians: Men > 102cm (40inches); Women >88cm (34inches)
    • Asians: Men> 90cm (35inches); Women 80cm (31inches)

Exclusion Criteria:

  • Those unable to give written informed consent
  • Those unwilling to provide general practitioner (GP) details
  • Regular prescribed medication that may affect study outcome. This will be assessed on an individual basis-not including statins
  • Over-the-counter (non-prescribed) medication that may affect the study data. This will be assessed on an individual basis.
  • Allergy to the test juice drink or the actual fruit itself
  • Chronic medical conditions requiring active treatment. This will be assessed on an individual basis
  • Those already consuming blood orange juice, unless they are willing to discontinue consumption for 2 weeks prior to starting the study.
  • Diagnosed diabetics;
  • Peri-menopausal women (defined as: when there is a permanent change in menstrual cycle)
  • Women on hormone replacement therapy (HRT) for less than one year
  • On thyroxine for less than one year
  • Women who are pregnant, have been pregnant within the last 12 months or who are breastfeeding
  • Those taking aspirin (prescribed or self-prescribed)
  • All blood pressure medication
  • Those individuals who happen to be on statins will be excluded if they have been on statins for less than 3 months; or if they are not taking on a daily basis; or those who have recently changed their dosage of statins. This will be assessed on an individual basis
  • Those on regular medication for hypercoagulation and inflammatory conditions e.g. corticosteroids and asthma. The intermittent use of an inhaler will be discussed on an individual basis
  • Those who have had a cardiovascular event such as stroke, myocardial infarction (heart attack) or trans ischemic attacks in the past and deemed unsuitable for participation in the study. This will be discussed with the medical adviser on an individual basis
  • Peripheral vascular disease including claudication
  • Consumption of fish oil supplements (unless participant is willing to discontinue their use 8 weeks prior to the start of the intervention- all other supplements will be assessed on an individual basis
  • Parallel participation in another research project which has involved dietary intervention and/or sampling of blood
  • Any person related to or living with any member of the study team
  • Participation in another research project which involves blood sampling within the last four months unless the total blood from both studies (including this one) does not exceed 470mL)
  • Those who have donated or intend to donate blood within 16 weeks of the first and last study samples
  • Gastrointestinal disease (excluding hiatus hernia) unless symptomatic or study intervention/procedure is contraindicated
  • Those undergoing any on-going clinical investigations with their GP or hospital clinic.
  • Those who have had throat surgery or neck injury
  • Those with internal medical devices

Screening exclusion criteria

  • Results of the eligibility screening that indicate or are judged by the Institute of Food Research Human Nutrition Unit (HNU) medical adviser to be indicative of a health problem which could compromise the well-being of the participant if they participated or could affect the study data.
  • BMI <19.5
  • Weight >180kg (28stones)
  • Fasting total cholesterol > 8.0mmol/L
  • Haemoglobin Men <13.8g/dL (8.56mmol/L) Women <12.1g/dL (<5.51mmol/L)
  • Fasting glucose >6mmol/L
  • Blood pressure <90/50mmHg or 95/55mmHg if symptomatic; >160/100mmHg
  • Anyone with any internal medical devices (incompatible with the TANITA)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02195934


Locations
United Kingdom
Institute of Food Research
Norwich, Norfolk, United Kingdom, NR4 7UA
Sponsors and Collaborators
Quadram Institute
European Commission
Biotechnology and Biological Sciences Research Council
Investigators
Study Director: Paul A Kroon, PhD Quadram Institute
Principal Investigator: Charlotte N Armah, PhD Quadram Institute
Principal Investigator: Joanne F Doleman, PhD Quadram Institute
  More Information

Responsible Party: Quadram Institute
ClinicalTrials.gov Identifier: NCT02195934     History of Changes
Other Study ID Numbers: IFR03/2014
14/EE/0219 ( Other Identifier: NRES Committee East of England - Norfolk )
155431 ( Other Identifier: NIHR Coordinated System for Gaining NHS permission (NIHR CSP) )
2014GP23 ( Other Identifier: South Norfolk CCG )
First Submitted: July 18, 2014
First Posted: July 21, 2014
Last Update Posted: September 5, 2016
Last Verified: April 2016

Keywords provided by Quadram Institute:
Cardiovascular disease, blood orange juice, anthocyanins

Additional relevant MeSH terms:
Cardiovascular Diseases